| 0.75 -0.043 (-5.43%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.11 |
1-year : | 1.28 |
| Resists | First : | 0.95 |
Second : | 1.1 |
| Pivot price | 0.94 |
|||
| Supports | First : | 0.73 |
Second : | 0.6 |
| MAs | MA(5) : | 0.81 |
MA(20) : | 0.95 |
| MA(100) : | 0.78  |
MA(250) : | 0.86 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 5.2 |
D(3) : | 6.6 |
| RSI | RSI(14): 33.3 |
|||
| 52-week | High : | 1.37 | Low : | 0.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALGS ] has closed above bottom band by 3.1%. Bollinger Bands are 97.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.8 - 0.81 | 0.81 - 0.81 |
| Low: | 0.72 - 0.72 | 0.72 - 0.73 |
| Close: | 0.74 - 0.75 | 0.75 - 0.76 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Thu, 11 Apr 2024
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest - MarketBeat
Tue, 09 Apr 2024
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry - Simply Wall St
Wed, 27 Mar 2024
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Thu, 14 Mar 2024
Aligos Therapeutics on the Brink: The Urgent Race to Maintain Nasdaq Listing and Avoid Delisting Consequences ... - TipRanks
Fri, 23 Feb 2024
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues - Simply Wall St
Fri, 05 Jan 2024
Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 21 (%) |
| Held by Institutions | 62.4 (%) |
| Shares Short | 869 (K) |
| Shares Short P.Month | 369 (K) |
| EPS | -1.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.23 |
| Profit Margin | 0 % |
| Operating Margin | -942.7 % |
| Return on Assets (ttm) | -36.7 % |
| Return on Equity (ttm) | -89.5 % |
| Qtrly Rev. Growth | -24.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -79 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -0.56 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 3.5 |
| Price to Cash Flow | -0.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|